Cargando…
The safety concerns regarding immune checkpoint inhibitors in liver cancer patients rising mainly from CHB
Aim: To analyze the safety of immune checkpoint inhibitors in primary liver cancer patients and to identify the risk factors for immune-related adverse events (irAEs). Methods: The study enrolled 106 patients with primary liver cancer, including 81 with hepatocellular carcinoma and 25 with intrahepa...
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165088/ https://www.ncbi.nlm.nih.gov/pubmed/37168999 http://dx.doi.org/10.3389/fphar.2023.1164309 |